Physiological responses to protein aggregates: Fibrinolysis, coagulation and inflammation (new roles for old factors)

FEBS Letters

Volumn 583, Issue 16, 2009, Pages 2691-2699

  Gebbink, Martijn F B G ^a,b   Bouma, Barend ^a   Maas, Coen ^b   Bouma, Bonno N ^b  

^a Crossbeta Biosciences BV   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Amyloid; Crossbeta; Haemostasis; Misfolding

Indexed keywords

BLOOD CLOTTING FACTOR 12; BRADYKININ; FIBRIN; FIBRONECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR;

ALZHEIMER DISEASE; AMYLOIDOSIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CONFORMATIONAL TRANSITION; DRUG MECHANISM; FIBRINOLYSIS; HEMOSTASIS; HUMAN; IMMUNOGENICITY; INFLAMMATION; KALLIKREIN KININ SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN SYNTHESIS; SHORT SURVEY;

BLOOD COAGULATION; BRADYKININ; FACTOR XII; FIBRINOLYSIS; FIBRONECTINS; HEMOSTASIS; HUMANS; INFLAMMATION; KALLIKREINS; KININS; PROTEIN FOLDING; PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 68649088039     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.06.013     Document Type: Short Survey

References (135)

1. Tartaglia G.G., and Vendruscolo M. The Zyggregator method for predicting protein aggregation propensities. Chem. Soc. Rev. 37 (2008) 1395-1401
2. Rousseau F., Schymkowitz J., and Serrano L. Protein aggregation and amyloidosis: confusion of the kinds?. Curr. Opin. Struct. Biol. 16 (2006) 118-126
3. Herczenik E., and Gebbink M.F. Molecular and cellular aspects of protein misfolding and disease. FASEB J. 22 (2008) 2115-2133
4. Chiti, F. (2009) FEBS Lett., this issue.
5. Luheshi, L.M. and Dobson, C.M. (2009) Bridging the gap: from protein misfolding to protein misfolding diseases. FEBS Lett., doi:10.1016/j.febslet.2009.06.030.
6. Langkilde, A.E. and Vestergaard, B. (2009) Methods for structural characterization of prefibrillar intermediates and amyloid fibrils. FEBS Lett., doi:10.1016/j.febslet.2009.05.040.
7. Rochet J.C., and Lansbury Jr. P.T. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10 (2000) 60-68
8. Nelson R., and Eisenberg D. Structural models of amyloid-like fibrils. Adv. Protein Chem. 73 (2006) 235-282
9. Chiti F., and Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75 (2006) 333-366
10. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi G., Dobson C.M., and Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416 (2002) 507-511
11. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
12. Howlett G.J., and Moore K.J. Untangling the role of amyloid in atherosclerosis. Curr. Opin. Lipidol. 17 (2006) 541-547
13. Pattison J.S., and Robbins J. Protein misfolding and cardiac disease: establishing cause and effect. Autophagy 4 (2008) 821-823
14. Frokjaer S., and Otzen D.E. Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 4 (2005) 298-306
15. Maas C., Hermeling S., Bouma B., Jiskoot W., and Gebbink M.F. A role for protein misfolding in immunogenicity of biopharmaceuticals. J. Biol. Chem. 282 (2007) 2229-2236
16. Yerbury J.J., Stewart E.M., Wyatt A.R., and Wilson M.R. Quality control of protein folding in extracellular space. EMBO Rep. 6 (2005) 1131-1136
17. Maas C., Govers-Riemslag J.W., Bouma B., Schiks B., Hazenberg B.P., Lokhorst H.M., Hammarstrom P., ten C.H., de Groot P.G., Bouma B.N., and Gebbink M.F. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J. Clin. Invest. 118 (2008) 3208-3218
18. Kranenburg O., Bouma B., Kroon-Batenburg L.M., Reijerkerk A., Wu Y.P., Voest E.E., and Gebbink M.F. Tissue-type plasminogen activator is a multiligand cross-beta structure receptor. Curr. Biol. 12 (2002) 1833-1839
19. Macfarlane R.G. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 202 (1964) 498-499
20. Davie E.W., and Ratnoff O.D. Waterfall sequence for intrinsic blood clotting. Science 145 (1964) 1310-1312
21. Bouma B.N., von dem Borne P.A., and Meijers J.C. Factor XI and protection of the fibrin clot against lysis-a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb. Haemost. 80 (1998) 24-27
22. von dem Borne P.A., Meijers J.C., and Bouma B.N. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 86 (1995) 3035-3042
23. Gailani D., and Broze Jr. G.J. Factor XI activation in a revised model of blood coagulation. Science 253 (1991) 909-912
24. Naito K., and Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J. Biol. Chem. 266 (1991) 7353-7358
25. Margolis J. Initiation of blood coagulation by glass and related surfaces. J. Physiol. 137 (1957) 95-109
26. Silverberg M., and Diehl S.V. The autoactivation of factor XII (Hageman factor) induced by low-Mr heparin and dextran sulphate. The effect of the Mr of the activating polyanion. Biochem. J. 248 (1987) 715-720
27. Silverberg M. Hageman factor activation by polysaccharides: effect of molecular weight. Adv. Exp. Med. Biol. 247A (1989) 453-460
28. Kluft C. Determination of prekallikrein in human plasma: optimal conditions for activating prekallikrein. J. Lab Clin. Med. 91 (1978) 83-95
29. van der Graaf F., Keus F.J., Vlooswijk R.A., and Bouma B.N. The contact activation mechanism in human plasma: activation induced by dextran sulfate. Blood 59 (1982) 1225-1233
30. Fujikawa K., Heimark R.L., Kurachi K., and Davie E.W. Activation of bovine factor XII (Hageman factor) by plasma kallikrein. Biochemistry 19 (1980) 1322-1330
31. Bock P.E., Srinivasan K.R., and Shore J.D. Activation of intrinsic blood coagulation by ellagic acid: insoluble ellagic acid-metal ion complexes are the activating species. Biochemistry 20 (1981) 7258-7266
32. Kannemeier C., Shibamiya A., Nakazawa F., Trusheim H., Ruppert C., Markart P., Song Y., Tzima E., Kennerknecht E., Niepmann M., von Bruehl M.L., Sedding D., Massberg S., Gunther A., Engelmann B., and Preissner K.T. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc. Natl. Acad. Sci. USA 104 (2007) 6388-6393
33. Smith S.A., and Morrissey J.H. Polyphosphate as a general procoagulant agent. J. Thromb. Haemost. 6 (2008) 1750-1756
34. Bergamaschini L., Donarini C., Gobbo G., Parnetti L., and Gallai V. Activation of complement and contact system in Alzheimer's disease. Mech. Ageing Dev. 122 (2001) 1971-1983
35. Bergamaschini L., Donarini C., Foddi C., Gobbo G., Parnetti L., and Agostoni A. The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system. Neurobiol. Aging 22 (2001) 63-69
36. Joseph K., Shibayama Y., Nakazawa Y., Peerschke E.I., Ghebrehiwet B., and Kaplan A.P. Interaction of factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Abeta protein of Alzheimer's disease. Immunopharmacology 43 (1999) 203-210
37. Burch R.M., Connor J.R., and Tiffany C.W. The kallikrein-kininogen-kinin system in chronic inflammation. Agents Actions 27 (1989) 258-260
38. Zimmerli W., Huber I., Bouma B.N., and Lammle B. Purified human plasma kallikrein does not stimulate but primes neutrophils for superoxide production. Thromb. Haemost. 62 (1989) 1121-1125
39. Revak S.D., Cochrane C.G., Bouma B.N., and Griffin J.H. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J. Exp. Med. 147 (1978) 719-729
40. Koyama S., Sato E., Nomura H., Kubo K., Miura M., Yamashita T., Nagai S., and Izumi T. Bradykinin stimulates type II alveolar cells to release neutrophil and monocyte chemotactic activity and inflammatory cytokines. Am. J. Pathol. 153 (1998) 1885-1893
41. Brown N.J., Nadeau J.H., and Vaughan D.E. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb. Haemost. 77 (1997) 522-525
42. Brown N.J., Gainer J.V., Stein C.M., and Vaughan D.E. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 33 (1999) 1431-1435
43. Brown N.J., Gainer J.V., Murphey L.J., and Vaughan D.E. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 102 (2000) 2190-2196
44. DiScipio R.G. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 45 (1982) 587-595
45. Ghebrehiwet B., Silverberg M., and Kaplan A.P. Activation of the classical pathway of complement by Hageman factor fragment. J. Exp. Med. 153 (1981) 665-676
46. Wiggins R.C., Giclas P.C., and Henson P.M. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J. Exp. Med. 153 (1981) 1391-1404
47. Caliezi C., Wuillemin W.A., Zeerleder S., Redondo M., Eisele B., and Hack C.E. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol. Rev. 52 (2000) 91-112
48. Merkulov S., Zhang W.M., Komar A.A., Schmaier A.H., Barnes E., Zhou Y., Lu X., Iwaki T., Castellino F.J., Luo G., and McCrae K.R. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 111 (2008) 1274-1281
49. Shariat-Madar Z., Mahdi F., Warnock M., Homeister J.W., Srikanth S., Krijanovski Y., Murphey L.J., Jaffa A.A., and Schmaier A.H. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood 108 (2006) 192-199
50. Hashimoto K., Hamamoto H., Honda Y., Hirose M., Furukawa S., and Kimura E. Changes in components of kinin system and hemodynamics in acute myocardial infarction. Am. Heart J. 95 (1978) 619-626
51. Xia C.F., Yin H., Borlongan C.V., Chao L., and Chao J. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension 43 (2004) 452-459
52. Xia C.F., Yin H., Yao Y.Y., Borlongan C.V., Chao L., and Chao J. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum. Gene Ther. 17 (2006) 206-219
53. Xia C.F., Smith Jr. R.S., Shen B., Yang Z.R., Borlongan C.V., Chao L., and Chao J. Postischemic brain injury is exacerbated in mice lacking the kinin B2 receptor. Hypertension 47 (2006) 752-761
54. Doggen C.J., Rosendaal F.R., and Meijers J.C. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 108 (2006) 4045-4051
55. Endler G., Marsik C., Jilma B., Schickbauer T., Quehenberger P., and Mannhalter C. Evidence of a U-shaped association between factor XII activity and overall survival. J. Thromb. Haemost. 5 (2007) 1143-1148
56. Cichon S., Martin L., Hennies H.C., Muller F., Van D.K., Karpushova A., Stevens W., Colombo R., Renne T., Drouet C., Bork K., and Nothen M.M. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am. J. Hum. Genet. 79 (2006) 1098-1104
57. Curd J.G., Prograis Jr. L.J., and Cochrane C.G. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J. Exp. Med. 152 (1980) 742-747
58. Costa-Neto C.M., Llenburg-Pilla P., Heinrich T.A., Parreiras-e-Silva L.T., Pereira M.G., Reis R.I., and Souza P.P. Participation of kallikrein-kinin system in different pathologies. Int. Immunopharmacol. 8 (2008) 135-142
59. Jozwiak L., Drop A., Buraczynska K., Ksiazek P., Mierzicki P., and Buraczynska M. Association of the human bradykinin B2 receptor gene with chronic renal failure. Mol. Diagn. 8 (2004) 157-161
60. Gao B.B., Chen X., Timothy N., Aiello L.P., and Feener E.P. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J. Proteome Res. 7 (2008) 2516-2525
61. Bergamaschini L., Parnetti L., Pareyson D., Canziani S., Cugno M., and Agostoni A. Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 12 (1998) 102-108
62. McLaren M., Alkaabi J., Connacher M., Belch J.J., and Valenete E. Activated factor XII in rheumatoid arthritis. Rheumatol. Int. 22 (2002) 182-184
63. Espinola R.G., Uknis A., Sainz I.M., Isordia-Salas I., Pixley R., DeLa C.R., Long W., Agelan A., Gaughan J., Adam A., and Colman R.W. A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis. Am. J. Pathol. 165 (2004) 969-976
64. Colman R.W. Plasma and tissue kallikrein in arthritis and inflammatory bowel disease. Immunopharmacology 43 (1999) 103-108
65. Becker C.G., Dubin T., and Glenn F. Induction of acute cholecystitis by activation of factor XII. J. Exp. Med. 151 (1980) 81-90
66. Kahn R., Herwald H., Muller-Esterl W., Schmitt R., Sjogren A.C., Truedsson L., and Karpman D. Contact-system activation in children with vasculitis. Lancet 360 (2002) 535-541
67. Frick I.M., Bjorck L., and Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb. Haemost. 98 (2007) 497-502
68. Hack C.E., and Colman R.W. The role of the contact system in the pathogenesis of septic shock. Sepsis 3 (1999) 111-118
69. Dotsenko V.L., Nenasheva N.M., Neshkova E.A., Morozova N.A., and Yarovaya G.A. Mechanism of activation of the kallikrein-kinin system in plasma of patients with atopic allergic diseases. Adv. Exp. Med. Biol. 247B (1989) 515-521
70. Atkins P.C., Miragliotta G., Talbot S.F., Zweiman B., and Kaplan A.P. Activation of plasma Hageman factor and kallikrein in ongoing allergic reactions in the skin. J. Immunol. 139 (1987) 2744-2748
71. Shcherbakova I., Neshkova E., Dotsenko V., Platonova T., Shcherbakova E., and Yarovaya G. The possible role of plasma kallikrein-kinin system and leukocyte elastase in pathogenesis of schizophrenia. Immunopharmacology 43 (1999) 273-279
72. Vaziri N.D., Toohey J., Powers D., Keegan K., Gupta A., Alikhani S., Mashood M., and Barbari A. Activation of intrinsic coagulation pathway in pre-eclampsia. Am. J. Med. 80 (1986) 103-107
73. Matsubayashi H., Sugi T., Suzuki T., Uchida N., Atsumi H., Izumi S., and Mikami M. Decreased factor XII activity is associated with recurrent IVF-ET failure. Am. J. Reprod. Immunol. 59 (2008) 316-322
74. Ogasawara M.S., Aoki K., Katano K., Ozaki Y., and Suzumori K. Factor XII but not protein C, protein S, antithrombin III, or factor XIII is a predictor of recurrent miscarriage. Fertil. Steril. 75 (2001) 916-919
75. Ogasawara M.S., Iinuma Y., Aoki K., Katano K., Ozaki Y., and Suzumori K. Low-dose aspirin is effective for treatment of recurrent miscarriage in patients with decreased coagulation factor XII. Fertil. Steril. 76 (2001) 203-204
76. Pauer H.U., Burfeind P., Kostering H., Emons G., and Hinney B. Factor XII deficiency is strongly associated with primary recurrent abortions. Fertil. Steril. 80 (2003) 590-594
77. Maeda H., Wu J., Okamoto T., Maruo K., and Akaike T. Kallikrein-kinin in infection and cancer. Immunopharmacology 43 (1999) 115-128
78. van Zonneveld A.J., Veerman H., and Pannekoek H. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid. J. Biol. Chem. 261 (1986) 14214-14218
79. Stack S., Gonzalez-Gronow M., and Pizzo S.V. Regulation of plasminogen activation by components of the extracellular matrix. Biochemistry 29 (1990) 4966-4970
80. Silverstein R.L., Leung L.L., Harpel P.C., and Nachman R.L. Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator. J. Clin. Invest. 74 (1984) 1625-1633
81. Borza D.B., and Morgan W.T. Acceleration of plasminogen activation by tissue plasminogen activator on surface-bound histidine-proline-rich glycoprotein. J. Biol. Chem. 272 (1997) 5718-5726
82. Sheng S., Truong B., Fredrickson D., Wu R., Pardee A.B., and Sager R. Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc. Natl. Acad. Sci. USA 95 (1998) 499-504
83. Lind S.E., and Smith C.J. Actin stimulates plasmin generation by tissue and urokinase-type plasminogen activators. Arch. Biochem. Biophys. 307 (1993) 138-145
84. Tucker H.M., Kihiko-Ehmann M., Wright S., Rydel R.E., and Estus S. Tissue plasminogen activator requires plasminogen to modulate amyloid-beta neurotoxicity and deposition. J. Neurochem. 75 (2000) 2172-2177
85. Reijerkerk A., Mosnier L.O., Kranenburg O., Bouma B.N., Carmeliet P., Drixler T., Meijers J.C., Voest E.E., and Gebbink M.F. Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system. Mol. Cancer Res. 1 (2003) 561-568
86. Bobbink I.W., Tekelenburg W.L., Sixma J.J., de Boer H.C., Banga J.D., and de Groot P.G. Glycated proteins modulate tissue-plasminogen activator-catalyzed plasminogen activation. Biochem. Biophys. Res. Commun. 240 (1997) 595-601
87. Gebbink M.F., Claessen D., Bouma B., Dijkhuizen L., and Wosten H.A. Amyloids-a functional coat for microorganisms. Nat. Rev. Microbiol. 3 (2005) 333-341
88. Kingston I.B., Castro M.J., and Anderson S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Nat. Med. 1 (1995) 138-142
89. Wnendt S., Wetzels I., and Gunzler W.A. Amyloid beta peptides stimulate tissue-type plasminogen activator but not recombinant prourokinase. Thromb. Res. 85 (1997) 217-224
90. Ellis V., Daniels M., Misra R., and Brown D.R. Plasminogen activation is stimulated by prion protein and regulated in a copper-dependent manner. Biochemistry 41 (2002) 6891-6896
91. Radcliffe R., and Heinze T. Stimulation of tissue plasminogen activator by denatured proteins and fibrin clots: a possible additional role for plasminogen activator?. Arch. Biochem. Biophys. 211 (1981) 750-761
92. Radcliffe R. A critical role of lysine residues in the stimulation of tissue plasminogen activator by denatured proteins and fibrin clots. Biochim. Biophys. Acta 743 (1983) 422-430
93. Machovich R., and Owen W.G. Denatured proteins as cofactors for plasminogen activation. Arch. Biochem. Biophys. 344 (1997) 343-349
94. Machovich R., Komorowicz E., Kolev K., and Owen W.G. Facilitation of plasminogen activation by denatured prothrombin. Thromb. Res. 94 (1999) 389-394
95. Haddeland U., Bennick A., and Brosstad F. Stimulating effect on tissue-type plasminogen activator-a new and sensitive indicator of denatured fibrinogen. Thromb. Res. 77 (1995) 329-336
96. Haddeland U., Sletten K., Bennick A., Nieuwenhuizen W., and Brosstad F. Aggregated, conformationally changed fibrinogen exposes the stimulating sites for t-PA-catalysed plasminogen activation. Thromb. Haemost. 75 (1996) 326-331
97. Gebbink M.F., Voest E.E., and Reijerkerk A. Do antiangiogenic protein fragments have amyloid properties?. Blood 104 (2004) 1601-1605
98. Thompson W.D., Stirk C.M., Melvin W.T., and Smith E.B. Plasmin, fibrin degradation and angiogenesis. Nat. Med. 2 (1996) 493
99. Schielen W.J., Voskuilen M., Adams P.J., Tesser G.I., and Nieuwenhuizen W. Structural requirements of fibrinogen A alpha-(148-160) for the enhancement of the rate of plasminogen activation by tPA. Blood Coagul. Fibrinol. 1 (1990) 521-524
100. Syrovets T., and Simmet T. Novel aspects and new roles for the serine protease plasmin. Cell Mol. Life Sci. 61 (2004) 873-885
101. Tsirka S.E. Tissue plasminogen activator as a modulator of neuronal survival and function. Biochem. Soc. Trans. 30 (2002) 222-225
102. Jacobsen J.S., Comery T.A., Martone R.L., Elokdah H., Crandall D.L., Oganesian A., Aschmies S., Kirksey Y., Gonzales C., Xu J., Zhou H., Atchison K., Wagner E., Zaleska M.M., Das I., Arias R.L., Bard J., Riddell D., Gardell S.J., bou-Gharbia M., Robichaud A., Magolda R., Vlasuk G.P., Bjornsson T., Reinhart P.H., and Pangalos M.N. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc. Natl. Acad. Sci. USA 105 (2008) 8754-8759
103. Melchor J.P., Pawlak R., and Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J. Neurosci. 23 (2003) 8867-8871
104. Tucker H.M., Kihiko M., Caldwell J.N., Wright S., Kawarabayashi T., Price D., Walker D., Scheff S., McGillis J.P., Rydel R.E., and Estus S. The plasmin system is induced by and degrades amyloid-beta aggregates. J. Neurosci. 20 (2000) 3937-3946
105. Tsirka S.E., Gualandris A., Amaral D.G., and Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377 (1995) 340-344
106. Busuttil S.J., Ploplis V.A., Castellino F.J., Tang L., Eaton J.W., and Plow E.F. A central role for plasminogen in the inflammatory response to biomaterials. J. Thromb. Haemost. 2 (2004) 1798-1805
107. Groenning M., Norrman M., Flink J.M., van de W.M., Bukrinsky J.T., Schluckebier G., and Frokjaer S. Binding mode of thioflavin T in insulin amyloid fibrils. J. Struct. Biol. 159 (2007) 483-497
108. Groenning M., Olsen L., van de W.M., Flink J.M., Frokjaer S., and Jorgensen F.S. Study on the binding of thioflavin T to beta-sheet-rich and non-beta-sheet cavities. J. Struct. Biol. 158 (2007) 358-369
109. Bouma B., Maas C., Hazenberg B.P., Lokhorst H.M., and Gebbink M.F. Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J. Thromb. Haemost. 5 (2007) 1139-1142
110. Vroman L., and Adams A.L. Identification of rapid changes at plasma-solid interfaces. J. Biomed. Mater. Res. 3 (1969) 43-67
111. Soderquist M., and Walton A. Structural changes in proteins adsorbed on polymer surfaces. J. Colloid Interf. Sci 75 (1980) 386-397
112. Ter-Minassian-Saraga L. Protein denaturation on adsorption and water activity at interfaces: an analysis and suggestion. J. Colloid Interf. Sci 80 (1981) 393-401
113. Chan B.M.C., and Brash J.L. Conformational change in fibrinogen desorbed from glass surface. J. Colloid Interf. Sci 84 (2009) 263-265
114. Zhao H., Tuominen E.K., and Kinnunen P.K. Formation of amyloid fibers triggered by phosphatidylserine-containing membranes. Biochemistry 43 (2004) 10302-10307
115. Zhao H., Jutila A., Nurminen T., Wickstrom S.A., Keski-Oja J., and Kinnunen P.K. Binding of endostatin to phosphatidylserine-containing membranes and formation of amyloid-like fibers. Biochemistry 44 (2005) 2857-2863
116. Zhu M., Souillac P.O., Ionescu-Zanetti C., Carter S.A., and Fink A.L. Surface-catalyzed amyloid fibril formation. J. Biol. Chem. 277 (2002) 50914-50922
117. Samuel M., Pixley R.A., Villanueva M.A., Colman R.W., and Villanueva G.B. Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J. Biol. Chem. 267 (1992) 19691-19697
118. Vogler E.A., and Siedlecki C.A. Contact activation of blood-plasma coagulation. Biomaterials 30 (2009) 1857-1869
119. Manning M.C., Patel K., and Borchardt R.T. Stability of protein pharmaceuticals. Pharm. Res. 6 (1989) 903-918
120. Zhuo R., and Vogler E.A. Practical application of a chromogenic FXIIa assay. Biomaterials 27 (2006) 4840-4845
121. Maas C., Schiks B., Strangi R.D., Hackeng T.M., Bouma B.N., Gebbink M.F., and Bouma B. Identification of fibronectin type I domains as amyloid-binding modules on tissue-type plasminogen activator and three homologs. Amyloid 15 (2008) 166-180
122. Verheijen J.H., Caspers M.P., Chang G.T., de Munk G.A., Pouwels P.H., and Enger-Valk B.E. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J. 5 (1986) 3525-3530
123. Matsuka Y.V., Medved L.V., Brew S.A., and Ingham K.C. The NH2-terminal fibrin-binding site of fibronectin is formed by interacting fourth and fifth finger domains. Studies with recombinant finger fragments expressed in Escherichia coli. J. Biol. Chem. 269 (1994) 9539-9546
124. Nieuwenhuizen W. Fibrin-mediated plasminogen activation. Ann. N.Y. Acad. Sci. 936 (2001) 237-246
125. Doolittle R.F. Searching for differences between fibrinogen and fibrin that affect the initiation of fibrinolysis. Cardiovasc. Hematol. Agents Med. Chem. 6 (2008) 181-189
126. Hazenberg B.P., van Rijswijk M.H., Piers D.A., Lub-de Hooge M.N., Vellenga E., Haagsma E.B., Hawkins P.N., and Jager P.L. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am. J. Med. 119 (2006) 355.e15-355.e24
127. Hudry-Clergeon G., Freyssinet J.M., Torbet J., and Marx J. Orientation of fibrin in strong magnetic fields. Ann. N.Y. Acad. Sci 408 (1983) 380-387
128. Sanchez J., Elgue G., Larsson R., Nilsson B., and Olsson P. Surface-adsorbed fibrinogen and fibrin may activate the contact activation system. Thromb. Res. 122 (2008) 257-263
129. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bisio A., Capila I., Lansing J.C., Guglieri S., Fraser B., Al-Hakim A., Gunay N.S., Zhang Z., Robinson L., Buhse L., Nasr M., Woodcock J., Langer R., Venkataraman G., Linhardt R.J., Casu B., Torri G., and Sasisekharan R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat. Biotechnol. 26 (2008) 669-675
130. Kishimoto T.K., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., Lansing J.C., Sriranganathan N., Zhao G., Galcheva-Gargova Z., Al-Hakim A., Bailey G.S., Fraser B., Roy S., Rogers-Cotrone T., Buhse L., Whary M., Fox J., Nasr M., Dal Pan G.J., Shriver Z., Langer R.S., Venkataraman G., Austen K.F., Woodcock J., and Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med. 358 (2008) 2457-2467
131. Yan S.D., Stern D., Kane M.D., Kuo Y.M., Lampert H.C., and Roher A.E. RAGE-Abeta interactions in the pathophysiology of Alzheimer's disease. Restor. Neurol. Neurosci. 12 (1998) 167-173
132. Yan S.D., Zhu H., Zhu A., Golabek A., Du H., Roher A., Yu J., Soto C., Schmidt A.M., Stern D., and Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat. Med. 6 (2000) 643-651
133. El Khoury J.B., Moore K.J., Means T.K., Leung J., Terada K., Toft M., Freeman M.W., and Luster A.D. CD36 mediates the innate host response to beta-amyloid. J. Exp. Med. 197 (2003) 1657-1666
134. Deane R., Sagare A., and Zlokovic B.V. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr. Pharm. Des. 14 (2008) 1601-1605
135. Bouma B., Kroon-Batenburg L.M., Wu Y.P., Brunjes B., Posthuma G., Kranenburg O., de Groot P.G., Voest E.E., and Gebbink M.F. Glycation induces formation of amyloid cross-beta structure in albumin. J. Biol. Chem. 278 (2003) 41810-41819